Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study reviews the potential of dibenzo derivatives as safer cancer treatments but finds conflicting evidence about their effectiveness, possibly due to structural differences among the compounds, and reports no new results.

In this study, researchers investigated factors predicting resistance to clomiphene citrate in women with anovulatory PCOS, identifying AMH and SHBG levels as significant indicators, but they found no reliable thresholds for predicting resistance to the standard 50 mg/day dose.

This study found that tildacerfont treatment in males with congenital adrenal hyperplasia reduced androgen levels and improved markers of testicular function, suggesting potential benefits for male reproductive health.

This article reviews current diagnostic criteria and treatment strategies for polycystic ovary syndrome, highlighting the role and limitations of the Rotterdam criteria and anti-Müllerian hormone, but it reports no new findings.

This letter discusses potential hair loss effects of Hedgehog inhibitors but presents no new clinical findings, urging further exploration of this possible class effect.

In this analysis of the BRAVE-AA trials, a significant number of patients with severe alopecia areata treated with baricitinib reached complete or nearly complete scalp coverage (SALT score ≤10 or ≤5) over 52 weeks, particularly among those with less severe baseline characteristics.

This article examines current pharmacologic treatments for PCOS focusing on symptom-specific approaches, particularly the metabolic effects of therapies, but reports no new clinical findings.

This article discusses the mechanisms of hirsutism and acne in women, highlighting cyproterone acetate with ethinyloestradiol as an effective anti-androgen therapy in the UK, but it reports no new clinical findings.

This study found that a synthetic avicequinone C analogue, 5e, was significantly more potent in inhibiting steroid 5α-reductase type 1 activity in human keratinocytes compared to the original isolated compound.

Bicalutamide may take longer to work for female hair loss, and higher doses might be needed.

RF-mesotherapy with bicalutamide may be a promising new treatment for hair loss.

This study observed a strong overall reduction in the use of CPA/EE in the Netherlands, despite similar proportions of users with acne or other hyperandrogenic conditions before and after the referral procedure.

In this case report, two women with chronic alopecia areata and acute alopecia universalis experienced sustained and near-complete hair regrowth after over a year of treatment with oral ruxolitinib, without significant side effects.

This study explored the effects of MOTILIPERM on infertility in a rat model with varicocele and oxidative stress, reporting its potential therapeutic efficacy.

In this chemical investigation, cyclospongiaquinone 1 from the sponge Verongula cf. rigida showed strong steroid 5α-reductase inhibitory activity, comparable to that of finasteride.

This study found that topical rebamipide, originally a gastric ulcer medication, can activate hair follicle stem cells and promote hair regeneration by modulating dermal adipocyte metabolism, with potential targeting of the prostaglandin E receptor EP4.

This study found that both cyproterone acetate and spironolactone effectively reduced hair diameter and plasma testosterone levels in hirsute women, with no significant differences between the two treatments.

This article discusses the role of lifestyle changes and medication like metformin in managing insulin resistance and cardiovascular risk in women with polycystic ovary syndrome but reports no new clinical results.

In this study, baricitinib treatment led to significant regrowth of scalp, eyebrow, and eyelash hair in alopecia areata patients compared to placebo, with higher effectiveness seen at the 4-mg dose.

This study found that daily treatment with ritlecitinib 50 mg over 24 months reduced the number of patients in the highest categories of scalp hair loss, with improvements seen in patient responses over time.

This case study reports that abrocitinib therapy led to clinical remission of alopecia universalis in a patient with a history of drug-induced DRESS, suggesting its potential as a treatment option.

In this study, withdrawal of baricitinib therapy in patients with severe alopecia areata who had achieved hair regrowth led to a loss of benefit in almost all patients, suggesting that continued treatment is necessary to maintain hair regrowth.

This study reported a rare case of pityriasis rubra pilaris-like skin reaction in an 18-year-old woman after starting ponatinib treatment for relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia, which resolved after treatment adjustment and did not recur over 15 months.

This study found that resveratrol improved menstrual regularity and reduced hair loss in women with PCOS, but did not affect androgen levels or metabolic profiles.

This study found that cyclic MPA is as effective as OCPs in resuming ovulation among women with PCOS, offering a viable alternative for those who cannot or choose not to use OCPs.

This study identified seven novel CYP17A1 inhibitor scaffolds as potential leads for treating polycystic ovary syndrome through an in silico approach, demonstrating favorable interactions, drug-like properties, and predicted bioactivities warranting further experimental validation.

This study found that approximately 85% of adults with severe alopecia areata who responded to baricitinib at 52 weeks maintained their improvement over a span of four years.

This report describes the successful use of sonidegib in treating two cases of locally advanced basal cell carcinoma, leading to remission in both instances, and reducing lesions in a patient with Gorlin syndrome, while noting mild side effects consistent with the drug's known profile.

In an animal study, researchers observed that a newly synthesized deoxycholic acid derivative showed similar prostate protection effects to finasteride in Wistar rats while being less toxic.